TrialScope seeks to expedite clinical trials approval process with new UI

5th September 2019 (Last Updated December 23rd, 2019 09:32)

TrialScope has released a new version of its TrialScope Disclose platform to accelerate the review and approval process for clinical trial disclosure.

TrialScope has released a new version of its TrialScope Disclose platform to accelerate the review and approval process for clinical trial disclosure.

The platform features a revamped user interface (UI), which is designed to speed up sponsors’ review and approval process for registering and updating clinical trials with regulatory agencies.

TrialScope vice-president of global transparency Francine Lane said: “The new interface, including mobile compatibility, enables sponsors to maintain regulatory disclosure compliance more efficiently.”

The software version was developed in partnership with the company’s customers in TrialScope Labs, which are part of the customer outreach programme.

TrialScope noted that it considered several iterations of the new redesign and asked customers about their specifications.

A survey was sent to global study owners (GSOs), medical writers and reviewers/approvers for their response on prototypes.

The new UI allows a reviewer/approver to see an earlier version of the form and compare it to the most recent version. It highlights any modifications in-line within the form.

It offers reviewers and approvers visibility into previous and current versions to reduce the entire approval cycle in order to bring products to market more rapidly.

The company said dashboards and study properties help users navigate and narrow their focus to complete tasks quicker and more efficiently.

TrialScope director of Customer Success Jaclyn Spedaliere said: “The sheer intuitiveness of the new UI reduces the amount of training needed for new users. This is particularly helpful in terms of change management.”

TrialScope supports 16 of the top 20 industry clinical trial sponsors worldwide. The company provides solutions that optimise the efficiency of disclosure activities and maximise trial data transparency.